Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CureVac ( (CVAC) ) has shared an update.
On June 24, 2025, CureVac N.V. announced the results of its Annual General Meeting, where shareholders approved all proposals, including the appointment of Axel Sven Malkomes to the Management Board and the reappointment of several Supervisory Board members. The meeting also confirmed KPMG Accountants N.V. as the external auditors for 2026, reflecting a stable governance structure and continuity in its strategic direction.
The most recent analyst rating on (CVAC) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.
Spark’s Take on CVAC Stock
According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.
CureVac’s overall stock score reflects strong financial improvements and an attractive valuation. Technical analysis indicates bullish momentum, although the RSI suggests caution. The historical volatility in financial metrics remains a potential risk.
To see Spark’s full report on CVAC stock, click here.
More about CureVac
CureVac N.V. is a pioneering multinational biotech company founded in 2000, specializing in messenger RNA (mRNA) technology for human medicine. The company aims to enhance the efficacy, safety, and cost-effectiveness of mRNA therapeutics, focusing on infectious diseases and oncology. CureVac also develops prophylactic vaccines and treatments to enable the body to produce therapeutic proteins, with operations in Germany, the Netherlands, Belgium, Switzerland, and the U.S.
Average Trading Volume: 1,161,540
Technical Sentiment Signal: Buy
Current Market Cap: $1.22B
For an in-depth examination of CVAC stock, go to TipRanks’ Overview page.